The incidence of hypochondroplasia is not known, but it has been estimated to be about as common as achondroplasia, which is seen in around 1 in 15,000 to 40,000 births. BioMarin has said that ...

BioMarin (BMRN) announced positive new data from studies of Voxzogo in children with achondroplasia and in ongoing clinical trials ...

Achondroplasia is a type of dwarfism that affects the growth in children, leading to a short stature or small size. Achondroplasia is a rare genetic condition that affects one in every 15,000 to ...

BioMarin reported noteworthy regulatory advancements, including guidance on achondroplasia screening and extending Voxzogo availability to 47 countries, with ambitions to reach 60 markets by 2027.

(RTTNews) - BioMarin Pharmaceutical Inc. (BMRN) announced positive new data from studies of VOXZOGO in children with achondroplasia and in ongoing clinical trials investigating other skeletal ...

BioMarin Pharmaceutical BMRN is scheduled ... Since its commercial launch in 2021, sales of the achondroplasia drug Voxzogo have been experiencing rapid uptake, driven by strong prescription ...

Voxzogo, BioMarin's treatment for achondroplasia, has been a significant driver of growth for the company. In the fourth quarter of 2024, Voxzogo sales reached $184 million, surpassing consensus ...

BioMarin Pharmaceutical Inc., a biotechnology ... for the treatment of achondroplasia; NAGLAZYME, a recombinant form of N- acetylgalactosamine 4-sulfatase for patients with MPS VI; and PALYNZIQ ...

BioMarin reported an 18% revenue growth in 2024 with a 28.6% operating margin. The company aims for $4 billion in revenue by 2027 and a 40% operating margin by 2026. Voxogo's potential extends beyond ...

Voxzogo, BioMarin's treatment for achondroplasia, has been a significant driver of growth for the company. In the fourth quarter of 2024, Voxzogo sales reached $184 million, surpassing consensus ...